Gregg H Alton
CIK 1334682 · Chief Patient Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.10M
Companies
7
Total Filings
213
Lifetime Open-Market Net
-$173.46M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVAX | Director | 47,685 | $7.89 | $376.2K | $0 | 10 | 2026-06-23 |
| CORT | Director | — | $114.23 | — | $0 | 8 | 2026-05-26 |
| RENOVARO INC. (RENB) Delisted | Director | — | $1.54 | — | $0 | 2 | 2024-06-27 |
| RENOVARO INC. (ENOB) Delisted | Director | — | $0.70 | — | $0 | 3 | 2023-01-05 |
| GILD | Chief Patient Officer | 58,046 | $133.06 | $7.72M | -$173.46M | 180 | 2019-03-05 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Director | — | — | — | $0 | 1 | 2015-06-05 |
| Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Director | — | — | — | $0 | 9 | 2012-10-02 |
Recent Filings · Page 11 of 22
213 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-12-05 | GILD | Mixed | −1,000 | -$1.04M | EDGAR |
| 2012-11-05 | GILD | Mixed | −1,000 | -$882.5K | EDGAR |
| 2012-10-03 | GILD | Mixed | −1,000 | -$879.5K | EDGAR |
| 2012-10-02 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-09-06 | GILD | Mixed | −1,000 | -$656.0K | EDGAR |
| 2012-08-27 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-08-03 | GILD | Mixed | −1,000 | -$2.43M | EDGAR |
| 2012-07-31 | GILD | Mixed | — | -$2.35M | EDGAR |
| 2012-07-03 | GILD | Mixed | −267 | -$514.5K | EDGAR |
| 2012-06-05 | GILD | Mixed | −1,000 | -$256.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.